In This Article:
CALGARY, Alberta - (NewMediaWire) - August 08, 2024 - Ocumetics Technology Corp. ("Ocumetics") (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO), a pioneer in vision enhancement technology, is excited to announce the successful development of a new injector system specifically designed for implantation of the Ocumetics Accommodative Intraocular lens (the "Ocumetics Lens"). This achievement marks a significant milestone in Ocumetics' journey toward its first-in-human study scheduled for early 2025.
The new injector, meticulously crafted by Medicil, a renowned Swiss IOL (intraocular lens) injector manufacturer, is tailored to the unique specifications of the Ocumetics Lens, ensuring precise and efficient implantation. This development is crucial for optimizing the surgical procedure, performance, and patient outcomes of this innovative lens, which is designed to provide optimal visual performance at all distances and improved quality of life for individuals with visually significant cataracts.
"We are delighted to have completed the development of this specialized injector in collaboration with Medicil," said Dean Burns, CEO of Ocumetics. "Their expertise and commitment to quality have been instrumental in achieving this milestone. This advancement brings us one step closer to our goal of revolutionizing vision correction after cataract surgery with the Ocumetics Accommodative IOL."
"We are proud to partner with Medicil on this groundbreaking project," said Dr Garth Webb, Chief Scientist at Ocumetics. "Our team has worked diligently to develop an injector that meets the high standards that are part of our corporate culture at Ocumetics. We are excited to envision the potential impact this might have on the field of ophthalmology."
The development of the Ocumetics Lens injector is a pivotal step in preparation for the upcoming first-in-human study. This study, scheduled for early next year, is designed to evaluate the safety and efficacy of the Ocumetics Accommodative IOL in a clinical setting, providing crucial data to support future regulatory applications and commercialization.
For more information about Ocumetics Technology Corp. and our cutting-edge vision enhancement solutions, please visit Ocumetics.com.
About Ocumetics
Ocumetics Technology Corp. (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO) is a Canadian research and product development company that is dedicated to developing advanced vision correction solutions that enhance the quality of life for patients. Through innovative research and development, Ocumetics aims to transform the field of ophthalmology with state-of-the-art intraocular lenses and other vision-enhancing technologies.